Home > Back to Publisher > Report Information

Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies

Arrowhead Publishers
May 1, 2010
280 Pages - SKU: AH2717816

Abstract Table of Contents Search inside this report Related Reports

The era of Personalized Medicine is set to revolutionize the healthcare industry. As our knowledge of genetics and molecular biology rapidly expands, a personalized approach to medical care is becoming increasingly important. Not only does this paradigm promise to improve an individual’s treatment outcome and reduce healthcare expenditure, personalized medicine is set to transform the pharmaceutical/biotechnology and companion diagnostic markets.

Arrowhead’s Personalized Medicine 2010 report provides an in-depth assessment of this burgeoning market, and examines the major challenges that need to be overcome to maximize success.

Key features of Arrowhead’s Personalized Medicine 2010 include:

Case studies of leading pharmacogenomic products
Analysis of the personalized medicine market, including seven major market sales forecasts to 2016
Regulatory and legal issues surrounding personalized medicine
Payer reimbursement challenges
Marketing strategies to capitalize profits
Survey results from key opinion leaders across the life sciences industry

Key questions answered by Arrowhead’s Personalized Medicine 2010 include:

What are the major challenges in this market and how can these be overcome?
How will pharmacogenomics transform clinical trials?
What are the leading pharmacogenomic products on the market?
Who are the key players involved in the market and what strategies are they using to enhance product performance?
What pharmaceutical/biotechnology and diagnostic companies are seeking alliances in 2010?
How can company alliances maximize commercial success?

Chapter 1 Executive Summary: Scope of Personalized Medicine: Market Trends and R&D Insights; Methodology of Personalized Medicine: Market Trends and R&D Insights; Key challenges in the commercialization of personalized Medicine; Overview of current therapeutic applications of personalized Medicine; Market Potential of personalized Medicine; Strategic Implications of personalized Medicine
Chapter 2 Introduction to Personalized Medicine: How bio-molecular advances have influenced changes in the healthcare industry; What is personalized medicine?; What are pharmacogenomics and pharmacogenetics?; The history of personalized Medicine…the story so far; Timeline of Personalized Medicine; Why are personalized Medicine important?; Population and disease-based bio-banks; Increasing healthcare costs; The aging population; Rising R&D expenditure; Long development time; High risk venture for drug development companies; Personalized approach versus current treatment strategy…a patient case study; Increased efficacy; Reduced toxicity; Reduced hospitalization; Putting Personalized Medicine into Practice …a case study of CYP2D6
Chapter 3 Overview of Genomics and Proteomics: Genomics; Introduction to genomics; Mechanisms of gene modification, regulation and expression; Methylated Gene (meDNA) Patterns; RNA; Transcription Factors; Circulating Cell-free nucleic acids; Identification of the human genome; The Human Genome Project; The International HapMap Consortium; CDC and the development of the Centers for Genomics and Public Health; Genomic Research into Genetic Polymorphisms; Single Nucleotide Polymorphisms (SNPs); The SNP Consortium; Companies and academic centers involved in the SNP Consortium; Proteomics; Introduction to proteomics; Proteins; From genes to proteins; The human genome versus the proteome; The relationship between the proteome and the genome; Widespread genotyping and the creation of a genetic database; The pharmacogenetics knowledge base (PharmaGKB)
Chapter 4 Overview of Pharmacodiagnostics (IVDs): Predictive diagnostics; Roche AmpiChip P450 Test; Prognostic diagnostics; Pharmacogenetic testing; Tarceva; Xeloda; MabThera/Rituxan; Avastin; The Importance of Tissue banking…focus in oncology; Regulators response to emerging diagnostics
Chapter 5 Personalized Medicine R&D Optimization: Overview of standard clinical trials; Biomarkers for Personalized Medicine clinical trials; What are biomarkers?; Biomarkers of response; Biomarkers of Efficacy and dose; Safety biomarkers; Preclinical safety biomarkers; Clinical safety biomarkers; Implementing a biomarker strategy; Development of biomarkers; Biomarkers as clinical end points; Validating biomarkers with regulators; Biomarker Programs Created by Pharma; J&J; Novartis; Pfizer; Roche; GSK; Merck; Personalized Medicine and the Optimization of R&D; Identify patients to give maximum efficacy (responders versus non-responders); Predict Adverse Drug Reactions and Identify genotypes correlating to Adverse Drug Reactions; Develop targeted drugs for specific genetic disorders; Identify patients at different stages of a disease; Monitor clinical responders in novel and comparator drugs to allow potential strategic alliances; Identify patients with drug resistance; Alter clinical trial paradigms; Intro of Phase 0; End of Phase I and IIA; Adaptive Phase IIB and Phase III; Phase IV; Cheaper drug development
Chapter 6 Personalized Medicine Regulatory Issues: US Regulation; FDA Pharmacogenomic submissions; FDA Labeling and recommendations; FDA Voluntary Genomic Submissions Program; Critical Path by FDA; NIH Research Tools Policy; NIDDK model; FDA Pharmacogenetic approval for marketed drugs; EU Regulation; EMEA Pharmacogenomic submissions; EMEA Labeling and recommendations; EMEA Pharmacogenetic approval for marketed drugs; Japan Regulation; Global Personalized Medicine Harmonization: ICH; The Interdisciplinary Pharmacogenomic Review Group (IPRC)
Chapter 7 Personalized Medicine Ethical Issues: Informed consent; Electronic medical record standards; Adoption of electronic health records and healthcare IT (HIT); Protection of medical records and privacy; Nuffield Council on Bioethics; Equitable distribution of benefits; Prevention of discrimination; Administration of personalized Medicine; Limited to wealthy individuals/markets; Race issues BiDiL; Lack of Asian and African Research; Cost of genotyping; Guidelines for genetic screening; National Society of Genetic Counselors Guidelines for genetic testing; NSGC Recommendations for protocols relating to predisposition genetic testing
Chapter 8 Personalized Medicine Legal and Reimbursement Issues: Intellectual Property Issues; US Patent and Trade Office (USPTO); SNP Consortium; Payer reimbursement; Medicare; Medicaid; NICE
Chapter 9 Personalized Medicine Therapeutic Applications: Drug Metabolism: The Cytochrome System; CYP2D6; CYP2D6 polymorphic variations; Ultra rapid metabolizers; CYP2C19; CYP3A; CYP2C9; Oncology; 9.2.1 Breast cancer; Introduction to breast cancer; Epidemiology of breast cancer; Breast cancer Biomarkers; Prognostic tests; MammaPrint 42; Oncotype DX; Predictive Tests; Hormonal therapies; Taxanes/anthracyclines; Biologicals; Herceptin; Triple Negative breast cancer; Colorectal cancer; Introduction to Colorectal cancer; Epidemiology of Colorectal cancer; Colorectal Cancer Biomarkers; Prognostic tests; Predictive tests; Erbitux; Panitumumab; Lung cancer; Introduction to Lung Cancer; Epidemiology of Lung cancer; Lung Cancer Biomarkers; EGFR; Avastin; Tarceva; Iressa; Erbitux; CVS; CVD; Asthma; COPD; Indoctoral P2 Norvartis; Beta adrenergic receptor; RAS polymorphisms; Pgp; Thiazides; 825T allele; Statins; CNS; Improved diagnosis and follow up tools; Alzheimer’s disease; Introduction to Alzheimer's disease; Epidemiology of Alzheimer’s; Alzheimer’s Biomarkers; APOE4; Parkinson’s disease; Intro to Parkinson’s disease; Epidemiology of Parkinson’s disease; Parkinson’s Biomarkers; Depression; Introduction to Depression; Epidemiology of Depression; Pristiq Wyeth; Schizophrenia; Intro to Schizophrenia; Epidemiology of Schizophrenia; Schizophrenia Biomarkers; DAAO D-amino acid oxidase; Atomoxetine Strattera Eli Lilly ADHD
Chapter 10 Market Potential of Personalized Medicine: The end of the blockbuster? …Niche/ Orphan drug status markets and its benefits; Minimize failures of late-stage candidates; Cheaper drug development; Reviving Failed Drug Candidates; Expanding Indications for Launched Drugs; Arrowhead’s Personalized Drug Revenue Forecast 2004-2019
Chapter 11 Personalized Medicine Strategic Implications: An Interdisciplinary challenge...The Personalized Medicine Coalition Recommendations; Pharma Strategies; Biotech Strategies; Pharmacodiagnostic strategies; Company Alliances are fundamental; Independent biotech companies are driving the personalized medicine revolution; Successful Alliances

Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies

Share this report

Other tasks

Research Assistance

Related Markets

Companion Diagnostics Reports

Free Alert Me service